Repare Therapeutics Inc. Common Shares - RPTX STOCK NEWS

Repare Therapeutics (Nasdaq: RPTX) reported Q2 2024 financial results and provided business updates. The company reiterated its guidance on the MYTHIC trial data readout for Q4 2024. The FDA granted Fast Track designation for lunresertib in combination with camonsertib in platinum-resistant ovarian cancer. Positive initial data from Phase 1 MINOTAUR trial was presented, and the first patient was dosed in the camonsertib monotherapy NSCLC expansion of Phase 1/2 TRESR trial.

Financially, Repare reported $1.1M in Q2 revenue and $53.5M for the first half of 2024. Net R&D expenses were $30.1M, and G&A expenses were $8.3M. The net loss was $34.8M or $0.82 per share.

Repare Therapeutics announced positive initial data from their Phase 1 MINOTAUR trial, evaluating lunresertib in combination with FOLFIRI for advanced solid tumors.

The trial showed an overall response rate of 18.2% in heavily pretreated patients and a 51.5% clinical benefit rate. Among colorectal cancer (CRC) patients, 40% of irinotecan-naïve patients received treatment for over nine months.

The recommended Phase 2 dose (RP2D) was established at 60mg BID lunresertib continuous plus standard FOLFIRI. Importantly, the safety profile was consistent with FOLFIRI alone, with the most common serious adverse events being neutropenia and leukopenia.

These findings, presented at the ESMO GI Cancers Congress, suggest lunresertib combined with FOLFIRI could offer a new treatment option for patients with CCNE1 amplification and FBXW7 mutations, which lack approved therapies.

Repare Therapeutics (Nasdaq: RPTX) has dosed the first patient in the expansion of its TRESR clinical trial, focusing on camonsertib monotherapy for non-small cell lung cancer (NSCLC) with ATM mutations. This expansion follows the rapid return of global rights to Repare. The TRESR trial aims to address the unmet need of over 5,000 patients with recurrent NSCLC in the US, UK, and top EU markets. Current treatments offer progression-free survival of around four months. The trial will enroll up to 20 patients to evaluate the efficacy of camonsertib at the recommended Phase 2 dose, with data expected in 2025.

Repare Therapeutics (Nasdaq: RPTX) has received Fast Track designation from the FDA for its combination therapy of lunresertib and camonsertib for treating platinum-resistant ovarian cancer in patients with specific genetic profiles (CCNE1 amplification, FBXW7, or PPP2R1A mutations). This treatment is currently in Phase 1 dose expansion trials. The FDA previously granted Fast Track designation for the same combination in treating endometrial cancer. Repare plans to present data from these trials in the fourth quarter of 2024, involving 20-30 patients each for ovarian and endometrial cancers. The Fast Track designation aims to expedite the development and review processes to bring significant new therapies to patients sooner.

Repare Therapeutics (Nasdaq: RPTX), a clinical-stage precision oncology company, announced that its senior management will participate in the Goldman Sachs 45th Annual Global Healthcare Conference.

The event will take place on June 10, 2024, at 2:40 p.m. Eastern Time in Miami, FL. The session will include a fireside chat, and a live webcast will be available on Repare's investor relations website.

The webcast replay will be accessible for 90 days post-event.

Repare Therapeutics (Nasdaq: RPTX) announced that initial data from its Phase 1 MINOTAUR study will be presented at the European Society of Medical Oncology (ESMO) GI Congress 2024. The study evaluates the efficacy of lunresertib (RP-6306) in combination with FOLFIRI for treating advanced solid tumors. This presentation is scheduled for June 27, 2024, at 3:35 PM CEST in Munich, Germany. The study aims to offer new insights into advanced gastrointestinal cancer treatments.

Repare Therapeutics Inc. reported financial results for Q1 2024, highlighting clinical progress in various programs. FDA agrees with RP2D for lunresertib plus camonsertib combo. Phase 2 TRESR expansion and Phase 1 LIONS monotherapy trial initiated. $237.0M in cash to fund operations till mid-2026. Camonsertib rights regained, new trial initiations, and board appointment announced. Revenue from collaboration agreements increased to $52.4M. Net income for Q1 2024 was $13.2M.

Repare Therapeutics and Debiopharm have dosed the first patient in the Phase 1/1b MYTHIC trial, evaluating the combination of PKMYT1 and WEE1 inhibition. This collaboration aims to assess safety, pharmacokinetics, and preliminary clinical activity of lunresertib and Debio 0123, showing promise for cancer patients.

Repare Therapeutics Inc. (Nasdaq: RPTX) appoints Dr. Steven H. Stein to its Board of Directors, thanking Todd Foley for his contributions. Dr. Stein brings extensive experience in oncology drug development, currently serving as the Chief Medical Officer of Incyte The Company looks forward to his guidance as it advances its precision oncology pipeline.